<DOC>
	<DOCNO>NCT00216827</DOCNO>
	<brief_summary>The purpose study evaluate whether daily treatment 8 week calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g ( dipropionate ) gel safe effective betamethasone 0.5 mg/g ( dipropionate ) gel vehicle , calcipotriol 50 mcg/g gel vehicle gel vehicle use alone patient scalp psoriasis . The primary outcome proportion patient absence disease mild disease 8 week treatment .</brief_summary>
	<brief_title>Efficacy Safety Calcipotriol Plus Betamethasone Gel Treatment Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Main Scalp psoriasis amenable topical treatment Psoriasis vulgaris trunk and/or limbs Extent scalp psoriasis involve 10 % total scalp area Disease severity scalp grade mild bad investigator Consenting outpatient 18 year Main PUVA Grenz ray therapy within 4 week prior randomisation UVB therapy within 2 week prior randomisation Systematic treatment biological therapy , possible effect scalp psoriasis within 6 month prior randomisation Systemic treatment therapy biologicals , possible effect scalp psoriasis ( e.g. , corticosteroid , vitamin D analogue , retinoids , immunosuppressant ) within 4 week prior randomisation Any topical treatment scalp ( except medicate shampoos emollient ) within 2 week prior randomisation Topical treatment face , trunk and/or limbs potent WHO group IV corticosteroid within 2 week prior randomisation Current diagnosis erythrodermic , exfoliative pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>